Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas

Anti-angiogenic therapy in glioblastoma (GBM) has unfortunately not led to the anticipated improvement in patient prognosis. We here describe how human GBM adapts to bevacizumab treatment at the metabolic level. By performing (13)C(6)-glucose metabolic flux analysis, we show for the first time that...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Acta Neuropathol
Prif Awduron: Fack, Fred, Espedal, Heidi, Keunen, Olivier, Golebiewska, Anna, Obad, Nina, Harter, Patrick N., Mittelbronn, Michel, Bähr, Oliver, Weyerbrock, Astrid, Stuhr, Linda, Miletic, Hrvoje, Sakariassen, Per Ø., Stieber, Daniel, Rygh, Cecilie B., Lund-Johansen, Morten, Zheng, Liang, Gottlieb, Eyal, Niclou, Simone P., Bjerkvig, Rolf
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Springer Berlin Heidelberg 2014
Pynciau:
Original Paper
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4282692/
https://ncbi.nlm.nih.gov/pubmed/25322816
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00401-014-1352-5
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg